A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma [SUBSTUDY OF 700197569]
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 May 2017
Price : $35 *
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Biomarker; Pharmacodynamics
- Acronyms ELO-1
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 04 Mar 2016 Planned primary completion date changed from 1 May 2016 to 1 Jul 2019 as per ClinicalTrials.gov record.
- 20 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.